Vtv Theraptcs Cl A (VTVT) 6.94 $VTVT vTv Therap
Post# of 273242
Posted On: 09/22/2016 7:13:45 AM
Vtv Theraptcs Cl A (VTVT) 6.94 $VTVT
vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference
BusinessWire - Thu Sep 08, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Company management will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The company's management will be presenting in the Holmes I room from 9:35 to 10:00am on September 12.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer's Disease
BusinessWire - Wed Sep 07, 6:00AM CDT
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo-controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), for treatment of mild Alzheimer's disease. Phase 3 follows a Phase 2b trial that demonstrated positive results in slowing cognitive decline with 5 mg/day of azeliragon in patients with mild to moderate Alzheimer's disease.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at the International Psychogeriatric Association International Congress
BusinessWire - Fri Sep 02, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD will be giving a platform presentation titled "Clinical Support for Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clinical Investigation for Mild Alzheimer's Disease" at the International Psychogeriatric Association International Congress on Wednesday, September 7 between 10:00 and 11:30am.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
BusinessWire - Tue Aug 16, 6:00AM CDT
--Company Releases Q2 Earnings Results and Details Upcoming Program Milestones
VTVT: 6.94 (-0.02)
CORRECTING and REPLACING vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
BusinessWire - Wed Aug 10, 6:51AM CDT
Please replace the release with the following corrected version due to multiple revisions.
VTVT: 6.94 (-0.02)
vTv Therapeutics Announces Positive Initial Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
BusinessWire - Wed Aug 10, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced positive topline results from a placebo and active-comparator-controlled Phase 2b clinical study of TTP399, a liver-selective glucokinase activator under development for the treatment of Type 2 diabetes.
VTVT: 6.94 (-0.02)
vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer's Association International Conference (AAIC)
BusinessWire - Wed Jul 27, 4:15PM CDT
--Azeliragon designed to inhibit RAGE, which affects AB accumulation, tau hyperphosphorylation and chronic inflammation
VTVT: 6.94 (-0.02)
vTv Therapeutics Reports First Quarter Financial and Operational Results
BusinessWire - Thu May 12, 3:05PM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today provided a corporate update and reported financial and operational results for the first quarter ended March 31, 2016.
VTVT: 6.94 (-0.02)
vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity
BusinessWire - Wed Apr 20, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that data from studies of its orally available, small molecule product candidates were reported at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. In an oral presentation later today, the Company will review clinical and preclinical data of TTP273, the first small molecule, orally active, GLP-1 receptor agonist (GLP-1R), which is currently in Phase 2 studies. The conference is being held in La Jolla, CA from April 17 - 20, 2016.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
BusinessWire - Tue Feb 09, 3:05PM CST
--Company expects to report topline results in mid-2016
VTVT: 6.94 (-0.02)
Is a Surprise Coming for vTv Therapeutics (VTVT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 10:01AM CST
vTv Therapeutics (VTVT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
VTVT: 6.94 (-0.02)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.62 (+0.06), JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), VTVT: 6.94 (-0.02), NVO: 46.04 (-0.19), ORMP: 7.69 (+0.13), AMGN: 173.85 (+0.47), GSK: 43.21 (+0.15)
vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Thu Jan 28, 3:05PM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 2:00pm EST. The conference will be held at The Waldorf Astoria in New York City.
VTVT: 6.94 (-0.02)
Volatility Creates Opportunity, Insights on Price Data - Research on vTv Therapeutics, Golden Entertainment, NCI Inc., and Avinger Inc.
ACCESSWIRE - Mon Dec 07, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: vTv Therapeutics Inc. (NASDAQ: VTVT), Golden Entertainment Inc. (NASDAQ: GDEN), NCI Inc. (NASDAQ: NCIT) and Avinger Inc. (NASDAQ: AVGR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AVGR: 4.61 (+0.02), VTVT: 6.94 (-0.02), NCIT: 11.36 (+0.14), GDEN: 12.74 (-0.13)
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
BusinessWire - Wed Dec 02, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical Officer. Altstiel brings decades of pharmaceutical industry experience and medical expertise to vTv, including serving in senior research and management roles at Pfizer Inc. and Eli Lilly Company. Most recently, Altstiel was Chief Executive Officer of Provectra Biotherapeutics where he led the company's mission in developing gene therapy for neuro-degenerative diseases.
VTVT: 6.94 (-0.02)
Equity Market Movement at a Glance - Research on vTv Therapeutics, Golden Entertainment, NCI, and AVINGER
ACCESSWIRE - Fri Nov 27, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / November 27, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: vTv Therapeutics Inc (NASDAQ: VTVT),Golden Entertainment Inc (NASDAQ: GDEN), NCI Inc (NASDAQ: NCIT) and AVINGER INC (NASDAQ: AVGR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AVGR: 4.61 (+0.02), VTVT: 6.94 (-0.02), NCIT: 11.36 (+0.14), GDEN: 12.74 (-0.13)
vTv Therapeutics to Participate in Fireside Chat at Piper Jaffray 27th Annual Healthcare Conference
BusinessWire - Tue Nov 24, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will participate in an analyst-led fireside chat at 4:00 p.m. EST on Wednesday, December 2 at the Piper Jaffray 27th Annual Healthcare Conference.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at Stifel 2015 Healthcare Conference
BusinessWire - Fri Nov 13, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, today announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will be presenting a corporate and clinical overview at the Stifel 2015 Healthcare Conference. The presentation will take place at 1:30 p.m. EST on Tuesday, November 17, 2015 at The New York Palace Hotel in New York City.
VTVT: 6.94 (-0.02)
vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015
BusinessWire - Thu Nov 12, 3:10PM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, today reported financial results for the third quarter of 2015 and provided an update on recent developments.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at the 8th Clinical Trials on Alzheimer's Disease (CTAD) Conference
BusinessWire - Thu Oct 22, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Dr. Marwan Sabbagh from the Barrow Neurological Institute, Principal Investigator for the ongoing Phase 3 Steadfast trial, will be presenting an evaluation of the Phase 2b safety study of azeliragon 20 mg/day and 5 mg/day in support of Phase 3 dose selection at the 8th Clinical Trials on Alzheimer's Disease (CTAD) conference. The oral presentation will take place on Friday, November 6 in Barcelona, Spain at 11:45 am CET (5:45 am EST).
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference
BusinessWire - Thu Sep 08, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Company management will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The company's management will be presenting in the Holmes I room from 9:35 to 10:00am on September 12.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer's Disease
BusinessWire - Wed Sep 07, 6:00AM CDT
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo-controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), for treatment of mild Alzheimer's disease. Phase 3 follows a Phase 2b trial that demonstrated positive results in slowing cognitive decline with 5 mg/day of azeliragon in patients with mild to moderate Alzheimer's disease.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at the International Psychogeriatric Association International Congress
BusinessWire - Fri Sep 02, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD will be giving a platform presentation titled "Clinical Support for Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clinical Investigation for Mild Alzheimer's Disease" at the International Psychogeriatric Association International Congress on Wednesday, September 7 between 10:00 and 11:30am.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
BusinessWire - Tue Aug 16, 6:00AM CDT
--Company Releases Q2 Earnings Results and Details Upcoming Program Milestones
VTVT: 6.94 (-0.02)
CORRECTING and REPLACING vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
BusinessWire - Wed Aug 10, 6:51AM CDT
Please replace the release with the following corrected version due to multiple revisions.
VTVT: 6.94 (-0.02)
vTv Therapeutics Announces Positive Initial Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
BusinessWire - Wed Aug 10, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced positive topline results from a placebo and active-comparator-controlled Phase 2b clinical study of TTP399, a liver-selective glucokinase activator under development for the treatment of Type 2 diabetes.
VTVT: 6.94 (-0.02)
vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer's Association International Conference (AAIC)
BusinessWire - Wed Jul 27, 4:15PM CDT
--Azeliragon designed to inhibit RAGE, which affects AB accumulation, tau hyperphosphorylation and chronic inflammation
VTVT: 6.94 (-0.02)
vTv Therapeutics Reports First Quarter Financial and Operational Results
BusinessWire - Thu May 12, 3:05PM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today provided a corporate update and reported financial and operational results for the first quarter ended March 31, 2016.
VTVT: 6.94 (-0.02)
vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity
BusinessWire - Wed Apr 20, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that data from studies of its orally available, small molecule product candidates were reported at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. In an oral presentation later today, the Company will review clinical and preclinical data of TTP273, the first small molecule, orally active, GLP-1 receptor agonist (GLP-1R), which is currently in Phase 2 studies. The conference is being held in La Jolla, CA from April 17 - 20, 2016.
VTVT: 6.94 (-0.02)
vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
BusinessWire - Tue Feb 09, 3:05PM CST
--Company expects to report topline results in mid-2016
VTVT: 6.94 (-0.02)
Is a Surprise Coming for vTv Therapeutics (VTVT) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 10:01AM CST
vTv Therapeutics (VTVT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
VTVT: 6.94 (-0.02)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.62 (+0.06), JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), VTVT: 6.94 (-0.02), NVO: 46.04 (-0.19), ORMP: 7.69 (+0.13), AMGN: 173.85 (+0.47), GSK: 43.21 (+0.15)
vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Thu Jan 28, 3:05PM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 2:00pm EST. The conference will be held at The Waldorf Astoria in New York City.
VTVT: 6.94 (-0.02)
Volatility Creates Opportunity, Insights on Price Data - Research on vTv Therapeutics, Golden Entertainment, NCI Inc., and Avinger Inc.
ACCESSWIRE - Mon Dec 07, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: vTv Therapeutics Inc. (NASDAQ: VTVT), Golden Entertainment Inc. (NASDAQ: GDEN), NCI Inc. (NASDAQ: NCIT) and Avinger Inc. (NASDAQ: AVGR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AVGR: 4.61 (+0.02), VTVT: 6.94 (-0.02), NCIT: 11.36 (+0.14), GDEN: 12.74 (-0.13)
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
BusinessWire - Wed Dec 02, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical Officer. Altstiel brings decades of pharmaceutical industry experience and medical expertise to vTv, including serving in senior research and management roles at Pfizer Inc. and Eli Lilly Company. Most recently, Altstiel was Chief Executive Officer of Provectra Biotherapeutics where he led the company's mission in developing gene therapy for neuro-degenerative diseases.
VTVT: 6.94 (-0.02)
Equity Market Movement at a Glance - Research on vTv Therapeutics, Golden Entertainment, NCI, and AVINGER
ACCESSWIRE - Fri Nov 27, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / November 27, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: vTv Therapeutics Inc (NASDAQ: VTVT),Golden Entertainment Inc (NASDAQ: GDEN), NCI Inc (NASDAQ: NCIT) and AVINGER INC (NASDAQ: AVGR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AVGR: 4.61 (+0.02), VTVT: 6.94 (-0.02), NCIT: 11.36 (+0.14), GDEN: 12.74 (-0.13)
vTv Therapeutics to Participate in Fireside Chat at Piper Jaffray 27th Annual Healthcare Conference
BusinessWire - Tue Nov 24, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will participate in an analyst-led fireside chat at 4:00 p.m. EST on Wednesday, December 2 at the Piper Jaffray 27th Annual Healthcare Conference.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at Stifel 2015 Healthcare Conference
BusinessWire - Fri Nov 13, 6:00AM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, today announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will be presenting a corporate and clinical overview at the Stifel 2015 Healthcare Conference. The presentation will take place at 1:30 p.m. EST on Tuesday, November 17, 2015 at The New York Palace Hotel in New York City.
VTVT: 6.94 (-0.02)
vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015
BusinessWire - Thu Nov 12, 3:10PM CST
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease (AD) and diabetes, today reported financial results for the third quarter of 2015 and provided an update on recent developments.
VTVT: 6.94 (-0.02)
vTv Therapeutics to Present at the 8th Clinical Trials on Alzheimer's Disease (CTAD) Conference
BusinessWire - Thu Oct 22, 6:00AM CDT
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Dr. Marwan Sabbagh from the Barrow Neurological Institute, Principal Investigator for the ongoing Phase 3 Steadfast trial, will be presenting an evaluation of the Phase 2b safety study of azeliragon 20 mg/day and 5 mg/day in support of Phase 3 dose selection at the 8th Clinical Trials on Alzheimer's Disease (CTAD) conference. The oral presentation will take place on Friday, November 6 in Barcelona, Spain at 11:45 am CET (5:45 am EST).
VTVT: 6.94 (-0.02)
(0)
(0)Scroll down for more posts ▼